Commercial Amino Acids
September 20, 2011
Wellesley, Mass. – In a recent release, COMMERCIAL AMINO ACIDS (BIO007J) from BCC Research (www.bccresearch.com), the U.S. market for amino acids was valued at nearly $1.8 billion in 2011. That value is projected to reach nearly $2.1 billion in 2016 after increasing at a five-year compound annual growth rate (CAGR) of 3.5%.
The U.S amino acids market can be broken down into three segments – flavorants, animal feeds, and specialties.
The segment made up of flavorants held a value of nearly $561 million in 2011 and is expected to grow at a CAGR of 3% to reach a value of $650 million in 2016.
The segment made up of animal feeds was worth more than $1 billion in 2011 and should be worth more than $1.2 billion in 2016, a CAGR of 3.9%.
The segment consisting of specialty amino acids was valued at $175 million in 2011 and in 2016 should be worth $203 million, a CAGR of 3%.
Amino acids gained commercial significance shortly after the turn of the century with the discovery of the flavor-enhancing quality of glutamic acid and the marketing of monosodium glutamate in Japan. Increased knowledge of the role amino acids play in the value of nutritional protein led to their use in fortifying animal feeds, as food supplements for humans, and sustaining seriously ill patients who had to be fed with intravenous solutions.
Since the 20 protein amino acids can be arranged in any order to make any number of polypeptides, their potential for a variety of inventions in the field of medicine is extraordinary. Their current uses in animal feed and food additives will continue to grow as there are no substitutes for amino acids and their value has been well proven.
As understanding of the functions and properties of amino acids increases, new commercial applications will enter development, while current commercial uses will continue expansion into worldwide markets.
This report will be of interest to those in the chemical industry, research institutions involved with the study of amino acids, amino acid manufacturers, industries that have amino acid byproducts, and also to senior market and planning executives, venture capitalists, and those interested in amino acid products.
Commercial Amino Acids( BIO007J )
Publish Date: Aug 2011
Data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. For media inquiries, email press@bccresearch.com or visit www.bccresearch.com/media to request access to our library of market research.
BCC Library Membership Benefits
Unlimited Access to Market Research Reports for Academic Institutions and Corporations.
Custom Research
Tailored solutions across industries for your unique business needs.
More in Cell Biology
- Biometrics as a Service in Medical Devices to Reach $2.7 Billion by 2030, Driven by Remote Patient Monitoring Demand
- Protein Synthesis Research Market to Reach $42.8 Billion by 2031, Driven by Surging CGT Investment
- AI and Advanced Diagnostics Transform Cancer Detection Market Amid Rising Healthcare Investment
- Cloud Computing in Cell Biology, Genomics and Drug Development to Reach $15.6 Billion by 2030 as Biological Data Explosion Drives Demand
- Decentralized Clinical Trials Market to Reach $18.8 Billion by 2030 as Digital Health Infrastructure Reshapes Drug Development
Reports from Cell Biology
Recent News
- Global Bispecific Antibodies Market to Reach $22.3 Billion by 2030 as Immuno-Oncology Innovation and R&D Investment Accelerate
- Global Noninvasive Cancer Diagnostics Market to Reach $165.2 Billion by 2030 as Liquid Biopsy, AI-Enabled Screening and Multi-Cancer Detection Tests Transform Oncology
- Neuroprotective Agents Market to Reach $60.9 Billion by 2030 as Neurological Disease Burden and Aging Populations Drive Pharmaceutical Investment
- Long-Term Care and Home Healthcare Technology Market to Reach $64.8 Billion by 2030 as Aging Demographics and Remote Monitoring Reshape Care Delivery
- Radioligand Therapeutics Market to More Than Double to $4.8 Billion by 2030 as Targeted Cancer Treatments Gain Regulatory Momentum